Liver Diseases  >>  Vanihep (vaniprevir)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vanihep (vaniprevir) / Merck (MSD)
NCT00518622: Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)

Checkmark
Jun 2013 - Jun 2013: 
Completed
1
40
US
Comparator: MK7009, MK7009, Comparator: Placebo
Merck Sharp & Dohme LLC
Hepatitis C
09/08
09/08
NCT01010906: A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)

Completed
1
60
NA
Vaniprevir 300 mg, MK-7009, Vaniprevir 200 mg
Merck Sharp & Dohme LLC
Hepatitis C
06/10
06/10
NCT00954993: Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)

Terminated
1
3
NA
Vaniprevir, MK-7009
Merck Sharp & Dohme LLC
Chronic Hepatitis C Infection
03/11
03/11

Download Options